Your browser doesn't support javascript.
loading
Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Rupoli, Serena; Canafoglia, Lucia; Goteri, Gaia; Leoni, Pietro; Brandozzi, Giuliano; Federici, Irene; Micucci, Giorgia; Giantomassi, Federica; Mozzicafreddo, Giorgio; Alterini, Renato; Filosa, Giorgio; Ricotti, Giuseppe; Simonacci, Marco; Scortechini, Anna Rita; Zizzi, Antonio; Pimpinelli, Nicola.
Afiliación
  • Rupoli S; Clinic of Hematology.
  • Canafoglia L; Clinic of Hematology.
  • Goteri G; Institute of Pathology.
  • Leoni P; Clinic of Hematology.
  • Brandozzi G; Clinic of Dermatology, AOU Ospedali Riuniti Umberto I, via Conca 71, 60126 Ancona, Italy.
  • Federici I; Clinic of Hematology.
  • Micucci G; Clinic of Hematology.
  • Giantomassi F; Institute of Pathology.
  • Mozzicafreddo G; Clinic of Dermatology, INRCA Ancona, Italy.
  • Alterini R; Division of Hematology, Dept. Clinical and Experimental Medicine.
  • Filosa G; Clinic of Dermatology, JESI.
  • Ricotti G; Clinic of Dermatology, INRCA Ancona, Italy.
  • Simonacci M; Clinic of Dermatology, Macerata, Italy.
  • Scortechini AR; Clinic of Hematology.
  • Zizzi A; Institute of Pathology.
  • Pimpinelli N; Division of Dermatology, Dept. Surgery and Translational Medicine, University of Florence Medical School, Italy.
Eur J Dermatol ; 26(1): 13-20, 2016.
Article en En | MEDLINE | ID: mdl-26678311
INTRODUCTION: Bexarotene is a synthetic retinoid effective in early and advanced stages of mycosis fungoides (MF)/Sezary Syndrome (SS) both in monotherapy and combination schemes. We aimed to assess disease response to low-dose bexarotene and PUVA in maintenance in refractory and/or resistant patients with early and advanced stage MF/SS. METHODS: We followed prospectively 21 patients (stages IB-IV): 15 with early stage MF and 6 with advanced disease. "Mini" and standard protocols were respectively applied to patients who failed PUVA or several systemic regimens. The dose of bexarotene and the administration of PUVA were titrated individually and tailored during induction and maintenance according to previous therapy, disease stage and toxicity. We evaluated overall response (OR) at the end of maintenance, safety and event-free survival (EFS). RESULTS: After induction phase, OR was 85.6%, higher in early MF (93.4%) than in advanced disease (66.6%). At the end of maintenance, OR was 76.2%, including 33.3% of CR. Median EFS for the whole group was 31 months. Bexarotene was well tolerated regarding the side effects, with prophylaxis and progressive drug increase in the induction phase of the protocol. Side effects were mainly of low and moderate grades. CONCLUSIONS: We observed a favorable rate of therapeutic effects and few, generally mild, side effects with low doses of bexarotene combined with PUVA.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fotoquimioterapia / Tetrahidronaftalenos / Micosis Fungoide / Anticarcinógenos Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Dermatol Asunto de la revista: DERMATOLOGIA Año: 2016 Tipo del documento: Article Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fotoquimioterapia / Tetrahidronaftalenos / Micosis Fungoide / Anticarcinógenos Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Dermatol Asunto de la revista: DERMATOLOGIA Año: 2016 Tipo del documento: Article Pais de publicación: Francia